Learn More
  • J P Fermand, P Ravaud, +9 authors J C Brouet
  • Blood
  • 1998
Results to date indicate that high-dose therapy (HDT) with autologous stem cell support improves survival of patients with symptomatic multiple myeloma (MM). We performed a multicenter, sequential, randomized trial designed to assess the optimal timing of HDT and autotransplantation. Among 202 enrolled patients who were up to 56 years old, 185 were randomly(More)
  • 1